First 3 runs free, then $50/run
    First 3 runs free, then $50/run

    Investment case

    SPDR S&P Biotech ETF

    XBI · 36 developments mapped · last assessed 2026-09-29

    Market Ontology has mapped 36 macro, policy, and market developments to SPDR S&P Biotech ETF since 2026-08-12. Each one is traced from the driver to the valuation assumption it moves, and the valuation below is run on the same engine the subscription uses.

    Last close
    Unavailable
    No published quote
    Market cap
    Unavailable
    Equity value
    Diluted shares
    Unavailable
    Latest reported
    Sector
    Unavailable
    Listing
    Unavailable
    Filings
    Unavailable
    No published filing

    Valuation

    No validated run has been published for XBI yet, so no modelled value is shown. The XBI valuation is in the public catch-up queue.

    Subscribers do not wait for the weekly cycle: they run XBI on demand, against live prices and the latest filings, and change any assumption the developments below move.

    Filed financials

    A validated filed-statement snapshot has not been published for XBI. Missing data is not estimated or replaced with scenario assumptions.

    Current case

    • Strongest support

      Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms

      Increased investor sentiment and capital flow into the biotechnology sector, particularly those focused on rare diseases and neurology.

      · Moves sector growth outlook, investor risk appetite

    • Main threat

      Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacks

      Sector sentiment. Significant setbacks for a prominent biotech company like Ionis can weigh on broader investor confidence in the sector, especially for companies with similar pipeline-driven risk profiles.

      · Moves overall sector risk premium, investor appetite for high risk, high reward biotech investments

    • Open question

      Electra Therapeutics Sets Nasdaq IPO Terms to Raise Up to $347M

      General sentiment towards the biotech sector and potential for new constituent.

      · Moves sector wide investor confidence, etf inflows/outflows

    What changed, by assumption

    Sector growth outlook
    • 2026-08-26Multiple System Atrophy Drug Pipeline Expands to 24 Clinical Candidates Across 22 Firms
    • 2026-08-21Werewolf Therapeutics and Ambros Therapeutics announce merger agreement and concurrent $150 million private placement
    Sector sentiment
    • 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17
    • 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/Share
    • 2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on Nasdaq
    • 2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per Share
    Overall investor risk appetite for biotech
    • 2026-09-03NEJM Publishes Revolution Medicines Daraxonrasib NSCLC Data: 42% ORR, 16.0 Mo Survival
    • 2026-09-12FDA Approves Isembyld for Spinal Muscular Atrophy
    Overall sector growth expectations
    • 2026-08-26FDA Approves Revolution Medicines' RASONQUE as First Targeted RAS Inhibitor
    Sector risk premium
    • 2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%
    • 2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacks
    • 2026-09-21Ionis Pharmaceuticals trades down 40% following late-stage clinical setbacks
    • 2026-09-02TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy

    Event impact log

    Full ledger →
    DateMechanismDirectionHorizonImpact
    2026-09-29Oncolytics Biotech Announces Publication of Pelareorep Data in Liver CancerBullish1-3m0.10
    2026-09-29Moleculin Biotech Completes Enrollment in Part A of Phase 2/3 R/R AML MIRACLE TrialBullish1-3m0.10
    2026-09-25ADARx Pharma Prices Upsized $446.3M IPO at $17 on NasdaqBullish1-5d0.40
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17 per ShareBullishintraday0.30
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Initial Public Offering at $17Bullish1-5d0.60
    2026-09-25ADARx Pharmaceuticals Prices Upsized $446.3M Nasdaq IPO at $17/ShareBullish1-3m0.60
    2026-09-24Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncologywatch1-3m0.20
    2026-09-23Longeveron Announces Exploration of All Options to Maximize Shareholder Value Following Phase 2b Trial ResultsBearish1-5d0.20
    2026-09-21Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 StudyBullish1-5d0.10
    2026-09-21Ionis slides over 40% year-to-date following late-stage clinical setbacksBearish1-5d0.20
    2026-09-21Bristol Myers Squibb Posts $12.9B Revenue as Growth Portfolio Hits 60%Bullish1-3m0.40
    2026-09-21Ionis Pharmaceuticals faces pipeline pressure after pelacarsen and eplontersen trial setbacksBearish1-3m0.40